- Home
- GGAL vs RGC Comparison
GGAL vs RGC Comparison
Compare GGAL & RGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GGAL | RGC |
|---|---|---|
| Founded | 1905 | 2014 |
| Country | Argentina | Hong Kong |
| Employees | N/A | N/A |
| Industry | Commercial Banks | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.7B | 9.8B |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | GGAL | RGC |
|---|---|---|
| Price | $53.67 | $33.68 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $67.50 | N/A |
| AVG Volume (30 Days) | ★ 1.1M | 362.2K |
| Earning Date | 03-07-2023 | 10-24-2025 |
| Dividend Yield | ★ 2.00% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.35 | N/A |
| Revenue | ★ $3,630,934,738.00 | N/A |
| Revenue This Year | $12.64 | N/A |
| Revenue Next Year | $18.04 | N/A |
| P/E Ratio | $16.82 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $25.89 | $0.09 |
| 52 Week High | $74.00 | $83.60 |
Technical Indicators
Market Signals| Indicator | GGAL | RGC |
|---|---|---|
| Relative Strength Index (RSI) | 54.25 | 77.24 |
| Support Level | $52.36 | $20.70 |
| Resistance Level | $56.28 | $25.50 |
| Average True Range (ATR) | 2.03 | 3.55 |
| MACD | 0.03 | 0.91 |
| Stochastic Oscillator | 61.75 | 89.57 |
Price Performance
Historical ComparisonAbout GGAL Grupo Financiero Galicia S.A.
Grupo Financiero Galicia SA is a financial service holding company. It provides general banking services, proprietary brand credit card services, personal loans, insurance, and other services. The company's operating business segments are Banks, Ecosistema Naranja X, Insurance, Adjustments, and Other Businesses. It generates maximum revenue from Banks. Geographically its operate in Argentina, Uruguay, and the majority of its revenue comes from Argentina.
About RGC Regencell Bioscience Holdings Limited
Regencell Bioscience Holdings Ltd is a bioscience company focusing on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degenerations, specifically ADHD and ASD, and infectious diseases affecting people's immune systems.